S1 Appendix -

S1A File. Community Survey–English. S1B File. Community Survey–Spanish. (ZIP)</p

Illustrative quotes for qualitative analysis of focus group themes.

Illustrative quotes for qualitative analysis of focus group themes.</p

Participant characteristics.

Participant characteristics.</p

Willingness to receive monoclonal antibody treatment for COVID-19 for Self and Others by Race/Ethnicity.

Willingness to receive monoclonal antibody treatment for COVID-19 for Self and Others by Race/Ethnicity.</p

Additional file 1 of Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients

Additional file 1: Figure S1. Maximum level of oxygenation support during the index hospitalization for patients who experienced treatment failure. IV: invasive mechanical ventilation; HFC: high flow nasal cannula; NIV: non-invasive ventilation

Additional file 5 of Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients

Additional file 5: Table S1. Medications and conditions used to stratify Mild versus Moderate/Severe immunocompromised status

Additional file 3 of Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients

Additional file 3: Figure S3. Adjusted risk difference and adjusted odds ratio (OR) for treatment failure for each risk factor from a conservative imputation model. In this model, we assumed all missing SARS-CoV-2 positive test dates were ten days prior to the mAb administration date. Risk differences were calculated via Firth's bias-reduced multiple regression logistic regression. Adjusted ORs and 95% confidence intervals (95% CI) were computed by penalized profile likelihood

Additional file 4 of Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients

Additional file 4: Figure S4. Adjusted risk difference and adjusted odds ratio (OR) for treatment failure for each risk factor from a conservative imputation model. In this model, we included only patients with confirmed dates for both SARS-CoV-2 positive test and mAb administration. Risk differences were calculated via Firth's bias-reduced multiple regression logistic regression. Adjusted ORs and 95% confidence intervals (95% CI) were computed by penalized profile likelihood

Additional file 2 of Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients

Additional file 2: Figure S2. Cumulative incidence of hazard for hospitalization by immunocompromised status